418 related articles for article (PubMed ID: 25751063)
1. A versatile modular vector system for rapid combinatorial mammalian genetics.
Albers J; Danzer C; Rechsteiner M; Lehmann H; Brandt LP; Hejhal T; Catalano A; Busenhart P; Gonçalves AF; Brandt S; Bode PK; Bode-Lesniewska B; Wild PJ; Frew IJ
J Clin Invest; 2015 Apr; 125(4):1603-19. PubMed ID: 25751063
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-mediated direct mutation of cancer genes in the mouse liver.
Xue W; Chen S; Yin H; Tammela T; Papagiannakopoulos T; Joshi NS; Cai W; Yang G; Bronson R; Crowley DG; Zhang F; Anderson DG; Sharp PA; Jacks T
Nature; 2014 Oct; 514(7522):380-4. PubMed ID: 25119044
[TBL] [Abstract][Full Text] [Related]
3. Repurposing CRISPR/Cas9 for in situ functional assays.
Malina A; Mills JR; Cencic R; Yan Y; Fraser J; Schippers LM; Paquet M; Dostie J; Pelletier J
Genes Dev; 2013 Dec; 27(23):2602-14. PubMed ID: 24298059
[TBL] [Abstract][Full Text] [Related]
4. Genome engineering using CRISPR-Cas9 system.
Cong L; Zhang F
Methods Mol Biol; 2015; 1239():197-217. PubMed ID: 25408407
[TBL] [Abstract][Full Text] [Related]
5. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
7. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9.
Abrahimi P; Chang WG; Kluger MS; Qyang Y; Tellides G; Saltzman WM; Pober JS
Circ Res; 2015 Jul; 117(2):121-8. PubMed ID: 25940550
[TBL] [Abstract][Full Text] [Related]
8. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract][Full Text] [Related]
9. CRISPR used to create mouse models.
Cancer Discov; 2014 Nov; 4(11):1248-9. PubMed ID: 25367932
[No Abstract] [Full Text] [Related]
10. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.
Aubrey BJ; Kelly GL; Kueh AJ; Brennan MS; O'Connor L; Milla L; Wilcox S; Tai L; Strasser A; Herold MJ
Cell Rep; 2015 Mar; 10(8):1422-32. PubMed ID: 25732831
[TBL] [Abstract][Full Text] [Related]
11. Targeting RLIP with CRISPR/Cas9 controls tumor growth.
Singhal J; Chikara S; Horne D; Awasthi S; Salgia R; Singhal SS
Carcinogenesis; 2021 Feb; 42(1):48-57. PubMed ID: 32426802
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma.
Brandt LP; Albers J; Hejhal T; Catalano A; Wild PJ; Frew IJ
PLoS One; 2017; 12(10):e0186102. PubMed ID: 28982163
[TBL] [Abstract][Full Text] [Related]
13. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids.
Dekkers JF; Whittle JR; Vaillant F; Chen HR; Dawson C; Liu K; Geurts MH; Herold MJ; Clevers H; Lindeman GJ; Visvader JE
J Natl Cancer Inst; 2020 May; 112(5):540-544. PubMed ID: 31589320
[TBL] [Abstract][Full Text] [Related]
14. New vectors for simple and streamlined CRISPR-Cas9 genome editing in Saccharomyces cerevisiae.
Laughery MF; Hunter T; Brown A; Hoopes J; Ostbye T; Shumaker T; Wyrick JJ
Yeast; 2015 Dec; 32(12):711-20. PubMed ID: 26305040
[TBL] [Abstract][Full Text] [Related]
15. Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future.
Mao XY; Dai JX; Zhou HH; Liu ZQ; Jin WL
Oncotarget; 2016 May; 7(22):33461-71. PubMed ID: 26993776
[TBL] [Abstract][Full Text] [Related]
16. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.
Dubrot J; Lane-Reticker SK; Kessler EA; Ayer A; Mishra G; Wolfe CH; Zimmer MD; Du PP; Mahapatra A; Ockerman KM; Davis TGR; Kohnle IC; Pope HW; Allen PM; Olander KE; Iracheta-Vellve A; Doench JG; Haining WN; Yates KB; Manguso RT
Immunity; 2021 Mar; 54(3):571-585.e6. PubMed ID: 33497609
[TBL] [Abstract][Full Text] [Related]
17. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
18. Adapting CRISPR/Cas9 for functional genomics screens.
Malina A; Katigbak A; Cencic R; Maïga RI; Robert F; Miura H; Pelletier J
Methods Enzymol; 2014; 546():193-213. PubMed ID: 25398342
[TBL] [Abstract][Full Text] [Related]
19. Practical Considerations for Using Pooled Lentiviral CRISPR Libraries.
McDade JR; Waxmonsky NC; Swanson LE; Fan M
Curr Protoc Mol Biol; 2016 Jul; 115():31.5.1-31.5.13. PubMed ID: 27366891
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Zhen S; Takahashi Y; Narita S; Yang YC; Li X
Oncotarget; 2017 Feb; 8(6):9375-9387. PubMed ID: 28030843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
